Madrigal Pharmaceuticals, Inc. (MDGL) Stock

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is led by CEO William J. Sibold, employs 915 people, headquartered in West Conshohocken, US, publicly traded since 2007.

Madrigal Pharmaceuticals, Inc. (MDGL) stock trades at $434.24 with a market capitalization of $10.03B. The stock is valued at a negative price-to-earnings (P/E) ratio of -39.10, reflecting a net loss over the last twelve months, price-to-book of 28.05, price-to-sales of 9.07. Over the past 52 weeks the stock has ranged between $393.61 and $615.00, and currently trades 29.4% below its 52-week high.

On profitability, Madrigal Pharmaceuticals, Inc. generates a return on equity (ROE) of -56.65% (negative, reflecting a net loss), return on capital employed of -37.06%, an operating margin of -27.68%, a net profit margin of -25.32%.

Madrigal Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Madrigal Pharmaceuticals, Inc. reported revenue of $0 rising to $958.0M. Compounded, revenue has grown —% a year over five years, —% over three, 432.2% over the last twelve months. Net profit fell to $-288.0M.

The most recent net margin is -25.32%. On a trailing twelve-month basis to Jun '26, revenue is $1.3B and net profit $-325.0M.

Borrowings stand at $354.0M, cash from operations was $-190.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -95.0% over five years, and was -47.8% in the most recent year.

The share price itself has compounded at 31.1% a year over five years, 20.3% over three, 69.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Madrigal Pharmaceuticals, Inc. (MDGL) — frequently asked questions